Bill

Bill > A4786


NJ A4786

NJ A4786
Requires performance of myeloma screening under certain circumstances.


summary

Introduced
10/17/2022
In Committee
10/17/2022
Crossed Over
Passed
Dead
01/08/2024

Introduced Session

2022-2023 Regular Session

Bill Summary

This bill requires the performance of a myeloma screening under certain circumstances. Under the bill, a licensed health care professional who performs an annual physical examination on a male patient is to include as part of that examination a screening for myeloma. Myeloma, also called multiple myeloma, is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect from infection. In a case of myeloma, cancerous plasma cells accumulate in the bone marrow and overcome healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. There are legislative findings and declarations in the bill, which include that African-American men have the highest myeloma incidence and death rates according to the American Cancer Society.

AI Summary

This bill requires licensed healthcare professionals to include a myeloma screening as part of the annual physical examination for male patients. Myeloma is a type of cancer that affects plasma cells, the white blood cells that produce antibodies. The bill cites legislative findings that men, and particularly African-American men, have higher incidence and mortality rates for myeloma compared to the general population. The bill aims to improve early detection and treatment of this disease through mandatory screening during routine checkups.

Committee Categories

Health and Social Services

Sponsors (2)

Last Action

Introduced, Referred to Assembly Health Committee (on 10/17/2022)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...